List of questions
Please tell me your assessment regarding the UK regulatory landscape preparedness and suitability for clinical translational research with specific focus on novel drug development and early phase trials. What are the major stumbling blocks in your view?
Does cancer immunotherapy have to be personalised?
As cancer antigens are unique to the patients tumours, immunotherapy HAS to be personalised.
How do we harness exisiting NHS expertise and resource to develop effective cancer immunotherapy that doesn't bancrupt the NHS?
The NHS has a number of BMT/HSCT facilities that provide cell based cancer treatments. These have the resources to develop cell-based cancer immunotherapy. Can we do this in Cambridge?